| Overview |
| bs-9512R |
| Protein S Polyclonal Antibody |
| WB, IHC-P, IHC-F, IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Protein S/PROS |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 5627 |
| P07225 |
| Preproprotein S; Propiece of latent protein S; PROS 1; PROS; PROS_HUMAN; PROS1; Protein S alpha; Protein Sa; PS 21; PS 22; PS 23; PS 24; PS 25; PS 26; PS21; PS22; PS23; PS24; PS25; PS26; PSA; Vitamin K dependent protein S; Vitamin K-dependent protein S. |
| Protein S (PROS) is a vitamin K-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated protein C (APC) and facilitates clearance of early apoptotic cells. In the plasma, circulating Protein S becomes inactive upon complexing with C4b-binding protein (C4BP); 60-70% of Protein S circulates in complex with C4BP. Calcium-dependent association of C4BP-Protein S with apoptotic cells influences the regulation of complement activation. Protein S has APC-independent anticoagulant activity through direct inhibition of prothrombin activation via interactions with Factor X A, Factor V A and phospholipids. Autosomal dominant Protein S deficiency (levels 15 to 37% of normal) correlates with severe recurrent venous thrombosis. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
IFIHC-P1:50-200 |
| IF |
|